Estrella Immunopharma (ESLA) Notes Payables (2022 - 2026)

Estrella Immunopharma (ESLA) posted quarterly Notes Payables of $465132.0 for Q1 2026, up 30.47% quarter-over-quarter from $356505.0 in Q4 2025.

Estrella Immunopharma (ESLA) Notes Payables (2022 - 2026) Analysis & Trends

Estrella Immunopharma (ESLA) has reported Notes Payables for 4 consecutive years, with $465132.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Notes Payables changed N/A year-over-year to $465132.0; the TTM figure through Mar 2026 stood at $465132.0 (changed N/A YoY), while the FY2025 annual figure was $356505.0, changed N/A from the prior year.
Notes Payables rose to $465132.0 in Q1 2026 per ESLA's latest filing, from $356505.0 in the prior quarter.
Across five years, Notes Payables topped out at $498600.0 in Q3 2022 and bottomed at $136533.0 in Q1 2023.
Historically, Notes Payables has averaged $325391.5 across 4 years, with a median of $328252.5 in 2023.
On a YoY basis, Notes Payables climbed as much as 39.83% in 2023 and fell as far as 39.83% in 2023.
Estrella Immunopharma's Notes Payables stood at $498600.0 in 2022, then slumped by 39.83% to $300000.0 in 2023, then advanced by 18.83% to $356505.0 in 2025, then jumped by 30.47% to $465132.0 in 2026.
Business Quant data shows ESLA's Notes Payables at $465132.0 in Q1 2026, $356505.0 in Q4 2025, and $385355.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-
10	Estrella Immunopharma	32.29 Mn	32.14 Mn	-

Download Data